Sign in
Not yet taking people in FrancePhase 1

Tests OT-C001 cell therapy in adults with relapsed or hard-to-treat large B-cell lymphoma

Tests OT-C001, a treatment made from natural killer immune cells, in adults with lymphoma.

Key facts

Who runs it
Emercell SAS
Where
Montpellier Cedex 05 and Toulouse Cedex 9, FranceSee the 2 sites
Registry title
A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma
Status
Not yet recruiting
Phase
Phase 1
People taking part
10 people, planned
Started
1 Jun 2025
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose diffuse large B-cell lymphoma has come back or has not responded to treatment. It tests the safety and activity of OT-C001, a natural killer cell therapy.

Age
18 years or older
Sex
All sexes can join
Disease stage
Diffuse large B-cell lymphoma that has relapsed (come back) or is refractory (did not respond to treatment)

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in France

  • CHU de MontpellierMontpellier Cedex 05, FranceNot yet recruiting
  • Oncopole Claudius RegaudToulouse Cedex 9, FranceNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Tests OT-C001 cell therapy in adults with relapsed or hard-to-treat large B-cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 November 2026